<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Hepatic arterial infusion chemotherapy for <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> is under evaluation because of the high target dose and low general toxicity </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate the efficacy and safety of a Folfox4 regimen administered through a combined hepatic arterial and systemic infusion for the first-line treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Twenty-seven <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> and no prior chemotherapy were enrolled into the study </plain></SENT>
<SENT sid="3" pm="."><plain>They received a Folfox4 regimen; 1st day: HAI of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> 85 mg/m(2) and L-folinic acid 200 mg/m(2), followed by a bolus hepatic arterial injection of <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> 400 mg/m(2), then continuous HAI of 5-FU 600 mg/m(2); 2nd day: infusion of L-folinic acid 200 mg/m(2) i.v. followed by an intravenous bolus injection of <z:chebi fb="0" ids="46345">5-Fluorouracil</z:chebi> 400 mg/m(2), then continuous infusion of <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> 600 mg/m(2) i.v </plain></SENT>
<SENT sid="4" pm="."><plain>The patients received HAI during the odd cycles, and the intravenous administration of the same Folfox4 regimen during the even cycles </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A total of 236 treatment cycles were given with a median of 10 cycles </plain></SENT>
<SENT sid="6" pm="."><plain>The therapy generated the following results after six treatment cycles: complete response (CR) 1/27 (3.7%), partial response (PR) 17/27 (63.0%), stable disease (SD) 6/27 (22.2%), and progress disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) 3/27 (11.1%) </plain></SENT>
<SENT sid="7" pm="."><plain>Five patients had hepatectomy </plain></SENT>
<SENT sid="8" pm="."><plain>The serum levels of both carcinoembryonic antigen (CEA) and CA19-9 were significantly reduced (P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>A median time to progression of 11 months and a median overall survival of 24 months were documented </plain></SENT>
<SENT sid="10" pm="."><plain>The major adverse events included grade 1/2 <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo>, upper <z:hpo ids='HP_0002027'>abdominal pain</z:hpo>, <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo>, and <z:hpo ids='HP_0001875'>neutropenia</z:hpo>/<z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The Folfox4 regimen administered through combined hepatic arterial and systemic infusions is efficacious and safe for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, and it facilitates the control of local lesions </plain></SENT>
</text></document>